rs376341076
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4BS2
This summary comes from the ClinGen Evidence Repository: The highest population minor allele frequency of the c.1684A>G (p.Thr562Ala) variant in CDKL5 in gnomAD v4.1 is 0.000004 in the European (Non-Finnish) population (not sufficient to meet BS1 criteria). The computational predictor REVEL gives a score of 0.133, evidence that does not predict a damaging effect on CDKL5 function (BP4). The p.Thr562Ala variant is observed in at least 2 unaffected individuals (Ambry Genetics: internal database, Labcorp Genetics Inc. (formerly Invitae): internal database) (BS2). In summary, the p.Thr562Ala variant in CDKL5 is classified as Likely Benign for CDKL5-associated disorder based on the ACMG/AMP criteria (BP4, BS2) (CDKL5 Specifications v.3.0; curation approved on 02/28/2025). LINK:https://erepo.genome.network/evrepo/ui/classification/CA10360405/MONDO:0100039/034
Frequency
Consequence
NM_001323289.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDKL5 | NM_001323289.2 | c.1684A>G | p.Thr562Ala | missense_variant | Exon 12 of 18 | ENST00000623535.2 | NP_001310218.1 | |
CDKL5 | NM_001037343.2 | c.1684A>G | p.Thr562Ala | missense_variant | Exon 13 of 22 | NP_001032420.1 | ||
CDKL5 | NM_003159.3 | c.1684A>G | p.Thr562Ala | missense_variant | Exon 12 of 21 | NP_003150.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000891 AC: 1AN: 112279Hom.: 0 Cov.: 23 AF XY: 0.00 AC XY: 0AN XY: 34443
GnomAD4 exome AF: 0.00000273 AC: 3AN: 1098214Hom.: 0 Cov.: 32 AF XY: 0.00000275 AC XY: 1AN XY: 363570
GnomAD4 genome AF: 0.00000891 AC: 1AN: 112279Hom.: 0 Cov.: 23 AF XY: 0.00 AC XY: 0AN XY: 34443
ClinVar
Submissions by phenotype
CDKL5 disorder Benign:2
The highest population minor allele frequency of the c.1684A>G (p.Thr562Ala) variant in CDKL5 in gnomAD v4.1 is 0.000004 in the European (Non-Finnish) population (not sufficient to meet BS1 criteria). The computational predictor REVEL gives a score of 0.133, evidence that does not predict a damaging effect on CDKL5 function (BP4). The p.Thr562Ala variant is observed in at least 2 unaffected individuals (Ambry Genetics: internal database, Labcorp Genetics Inc. (formerly Invitae): internal database) (BS2). In summary, the p.Thr562Ala variant in CDKL5 is classified as Likely Benign for CDKL5-associated disorder based on the ACMG/AMP criteria (BP4, BS2) (CDKL5 Specifications v.3.0; curation approved on 02/28/2025). -
This variant has been collected from RettBASE and curated to current modified ACMG/AMP criteria. Based on the classification scheme defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like Disorders Specifications to the ACMG/AMP Variant Interpretation Guidelines VCEP 3.0, this variant is classified as likely benign. At least the following criteria are met: The variant is observed in at least 2 individuals with no features of CDKL5 disorder (BS2). ClinVar Variation ID: 434666 There are 4 individuals in gnomAD v4 (1 hemizygote), AF <0.008% Computational prediction analysis tools suggest no impact on gene product (REVEL score <= 0.15) (BP4). -
not specified Uncertain:1
- -
Inborn genetic diseases Uncertain:1
The p.T562A variant (also known as c.1684A>G), located in coding exon 11 of the CDKL5 gene, results from an A to G substitution at nucleotide position 1684. The threonine at codon 562 is replaced by alanine, an amino acid with similar properties. This variant was previously reported in the SNPDatabase as rs376341076. Based on data from the NHLBI Exome Sequencing Project (ESP), the G allele was absent out of 2443 total male alleles studied. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Developmental and epileptic encephalopathy, 2;CN128785:Angelman syndrome-like Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at